Revalesio Reports Results from its Non-Clinical Study of RNS60 for Amyotrophic Lateral Sclerosis (ALS)
Shots:
- Revalesio highlighted non-clinical results of RNS60 in the ALS mouse models during the Nanosymposium ALS Therapeutics at the Society for Neuroscience Annual Meeting
- The study was carried out in PrpTDP-43A315T-UeGFP model of ALS that expressed mutated human TDP43 gene leading to motor neuron degeneration, muscle weakness & death
- The 30-day old ALS mice were treated with RNS60 for 60 days. RNS60 significantly improved mitochondrial structure in the motor neuron, decreased astrogliosis & microgliosis as well as protected upper motor neurons & neuromuscular junctions. Clinical studies to further develop RNS60 for ALS & ischemic stroke are planned
Ref: Revalesio | Image: Revalesio
Related News:- ReCode Therapeutics Reports the Preclinical Data of RCT2100 for Cystic Fibrosis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
